Antiviral Resistance and Phage Counter Adaptation to Antibiotic-Resistant Extraintestinal Pathogenic Escherichia coli-Reference-Cited by-同舟云学术

Antiviral Resistance and Phage Counter Adaptation to Antibiotic-Resistant Extraintestinal Pathogenic Escherichia coli

Published:2021-04-27 Issue:2 Volume:12 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Salazar Keiko C.¹²^ORCID,Ma Li³,Green Sabrina I.²,Zulk Jacob J.²,Trautner Barbara W.⁴⁵,Ramig Robert F.²,Clark Justin R.²,Terwilliger Austen L.²,Maresso Anthony W.²

Affiliation:

1. Department of Integrative Molecular and Biomedical Science, Baylor College of Medicine, Houston, Texas, USA

2. Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA

3. School of Biological and Physical Sciences, Northwestern State University, Natchitoches, Louisiana, USA

4. Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA

5. Department of Medicine, Baylor College of Medicine, Houston, Texas, USA

Abstract

Extraintestinal pathogenic Escherichia coli (ExPEC), often multidrug resistant (MDR), is a leading cause of urinary tract and systemic infections. The crisis of emergent MDR pathogens has led some to propose bacteriophages as a therapeutic.

Funder

HHS | National Institutes of Health

U.S. Department of Veterans Affairs

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mBio.00211-21

Reference89 articles.

1. World Health Organization. 2016. Antibiotic resistance fact sheet. World Health Organization Geneva Switzerland. http://www.who.int/mediacentre/factsheets/antibiotic-resistance/en/2016.

2. Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States. U.S. Centers for Disease Control and Prevention Atlanta GA.

3. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistantPseudomonas aeruginosa; a preliminary report of efficacy

4. Where are all the new antibiotics? The new antibiotic paradox

5. Extraintestinal pathogenic Escherichia coli : “The other bad E coli ”

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Variable fitness effects of bacteriophage resistance mutations in Escherichia coli: implications for phage therapy;Journal of Virology;2024-08-30

2. Antimicrobial resistance: use of phage therapy in the management of resistant infections;Molecular Biology Reports;2024-08-21

3. Does Phage Therapy Need a Pan-Phage?;Pathogens;2024-06-20

4. Appelmans protocol – A directed in vitro evolution enables induction and recombination of prophages with expanded host range;Virus Research;2024-01

5. Genome analysis of triple phages that curtails MDR E. coli with ML based host receptor prediction and its evaluation;Scientific Reports;2023-12-27